Welcome To 4th Microbiome Movement - Drug Development Summit

The study of the human microbiome remains one of the most exciting frontiers in modern medicine, that, if targeted correctly, has the potential to benefit millions of patients suffering from numerous diseases. However, the potential for effective disease treatment through the microbiome is matched by the unique challenges in developing them. The 4th Microbiome Movement – Drug Development Summit returns to help cutting-edge pharmaceutical and academic researchers pursue the causal role of the human microbiome in disease to help deliver a new generation of targeted therapeutics, biomarker and diagnostics to patients that demonstrate consistent clinical outcomes and mechanisms of action.

So whether you’re part of a microbiome-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the Microbiome Movement as we explore the global advances in translational microbiome research, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the human microbiome.

3 Streams Of Granular Scientific Content




Learn how leaders in the field are defining host microbiome interactions,
identifying new targets and addressing the current challenges in the pre-clinical
development of microbiome-based
therapeutics across a broad range of modalities and disease phenotypes.

Navigate through the evolving
translational, clinical, regulatory
and manufacturing challenges of
microbiome-based therapeutics to
help improve clinical outcomes
and bring these products to a
commercial scale.

Review research on the identification
of microbiome-derived biomarkers and
better understand their application to
help guide clinical development, and
as a patient stratification tool for predetermining therapeutic response across multiple disease phenotypes.

Hear What Our Customers Say

"As a newcomer to the microbiome field, this conference provided an excellent overview.”

Richard Shanksky
Seres  Therapeutics

“It was a great conference to effectively learn the current trends in microbiome drug development around the world.”

Nanae Izumi
Daiichi Sankyo